<DOC>
	<DOCNO>NCT00408395</DOCNO>
	<brief_summary>This study safety immunogenicity three commercially available influenza vaccine child .</brief_summary>
	<brief_title>Safety Immunogenicity 2 Commercially Available Influenza Vaccines Children</brief_title>
	<detailed_description>A Phase II , Observer-Blind , Randomized , Parallel Groups , Multicenter , Exploratory Clinical Study Evaluate Immunogenicity Safety One Two 0.25 mL Intramuscular Doses commercially available influenza vaccine versus Two 0.25 mL Intramuscular Doses commercially available influenza vaccine Healthy Children</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>6 month &lt; 36 month age Any severe acute respiratory disease infection require systemic antibiotic antiviral therapy ongoing resolve within 30 day prior study start ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) Other serious disease : cancer , autoimmune disease ( include rheumatoid arthritis ) , diabetes mellitus , chronic pulmonary disease , acute progressive hepatic renal disease , surgery plan study period . Known suspect impairment/alteration immune function History hypersensitivity component study vaccine , egg product vaccine component , impairment/alteration immune function</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>influenza</keyword>
	<keyword>child</keyword>
	<keyword>vaccine</keyword>
	<keyword>influenza disease</keyword>
</DOC>